SCHEMBL24090102

SCHEMBL24090102

CN(C)Cc1ccc(Nc2nc3ccc(C(F)(F)F)cc3c(=O)n2-c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.41
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
IDO2 Q6ZQW0 1/20 0.41
ACP1 P24666 2/20 0.40
CXCR3 P49682 3/20 0.40
MTOR P42345 1/20 0.38
LMNA P02545 1/20 0.38
G6PD P11413 1/20 0.37
TLR9 Q9NR96 1/20 0.37
MCHR1 Q99705 1/20 0.37
CTSD P07339 1/20 0.37
KDM1A O60341 1/20 0.37
LSS P48449 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24090006 0.88 TDO2 (0.51) IDO1TDO2IDO2ACP1
SCHEMBL24090150 0.88 LMNA (0.40) MAT2ALMNAG6PDTLR9CTSD
SCHEMBL24089901 0.88 G6PD (0.44) MAT2ALMNAG6PDTLR9CTSD
SCHEMBL24089969 0.87 IDO1 (0.42) IDO1TDO2IDO2ACP1
SCHEMBL29623309 0.86 ACP1 (0.48) MAT2AACP1KDM1A
SCHEMBL23045341 0.86 ACP1 (0.48) MAT2AACP1KDM1A
SCHEMBL24090135 0.85 USP2 (0.48) ACP1LMNA
SCHEMBL24089905 0.84 KDM1A (0.44) IDO1TDO2IDO2ACP1LMNA
SCHEMBL24089904 0.83 DHODH (0.43) MAT2AG6PDTLR9CTSD
SCHEMBL24089994 0.83 MAP3K7 (0.49) ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL MAT2A 4390/4885IDO1 386/4885TDO2 2059/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 MAT2A 4098/4885IDO1 592/4885TDO2 1774/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 MAT2A 4098/4885IDO1 592/4885TDO2 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.